米非司酮治疗子宫内膜异位症患者的临床观察

Clinical observation of Mifepristone in treatment of patients with endometriosis

目的:探讨孕激素拮抗剂米非司酮治疗子宫内膜异位症患者的临床疗效。方法:选择子宫内膜异位症患者110例,随机分为研究组和对照组,对照组患者使用安宫黄体酮20 mg/d治疗,研究组患者使用米非司酮12.5 mg/d治疗,两组患者均连续用药6个月,比较两组患者痛经、月经不调或腹部不适等症状缓解情况,随访一年记录复发率和妊娠率。结果:两组患者痛经、月经不调或腹部不适等症状均得到不同程度的缓解。研究组患者痊愈率和有效率显著高于对照组。随访一年,研究组患者复发率显著低于对照组,妊娠率显著高于对照组,均具有统计学差异(P<0.05)。结论:孕激素拮抗剂米非司酮治疗子宫内膜异位症疗效优于安宫黄体酮治疗效果。

Objective: To evaluate clinical efficacy of mifepristone,a progesterone antagonist,in the treatment of patients with endometriosis. Methods: 110 endometriosis patients were selected and divided into two groups randomly. The control group was given medroxy progesterone acetate at 20 mg / d for 6 months,the test group was given Mifepristone at 12. 5 mg / d for 6 months. The remissions of dysmenorrhea,irregular menstruation,abdominal discomfort and other symptoms of the two groups were compared. The recurrence rate and successful pregnancy rate were recorded in one- year follow- up. Results: Dysmenorrhea,irregular menstruation,abdominal discomfort and other symptoms of the two groups were alleviated to some extent. The cure rate and effective rate of test group were significantly higher than those of control group. The recurrence rate was significantly lower,and the successful pregnancy rate was significantly higher than those of control group,and there were statistically significant differences( P < 0. 05). Conclusions: Progesterone antagonist mifepristone is more effective in treating endometriosis than medroxy progesterone acetate.